Detail akcie CureVac Rg online

Business Summary: CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, CureVac BV revenues increased from EUR53.8M to EUR535.2M. Net income totaled EUR162.2M vs. loss of EUR260.2M. Revenues reflect Belgium (Country) segment increase from EUR47.1M to EUR519.9M, Switzerland segment increase from EUR5.4M to EUR12.9M, Netherlands segment increase of 99% to EUR2.4M. Net Income reflects Biopharmaceuticals segment income totaling EUR177.7M vs. loss of EUR274.2M.